India Clinical Trials Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report (2026-2035)

India’s clinical trial ecosystem is increasingly incorporating decentralised components such as remote monitoring, home health visits, telemedicine, electronic patient-reported outcomes and direct-to-patient medicine delivery. A 2026 Indian Journal of Medical Research study involving Indian clinical research professionals found that hybrid trials accounted for 71% of reported decentralised trial models, compared with 29% for fully decentralised trials. Home health visits and remote monitoring were each reported by 16% of respondents. Oncology, cardiovascular and metabolic studies represented notable application areas. The model is being used to reduce travel requirements and improve participant convenience, although digital literacy, infrastructure, regulatory uncertainty and data privacy remain implementation considerations.

India is building broader institutional networks to support multicentre clinical research and improve access to trial infrastructure outside major pharmaceutical hubs. The ICMR Clinical Trial and Education Network currently includes 75 sites for Phase II and III trials and four institutions for Phase I studies, bringing together public and private medical colleges, hospitals, research institutes and ICMR institutions. In 2026, ICMR also invited proposals for multicentre randomised controlled trials addressing non-communicable diseases, including studies incorporating digital health, lifestyle and behavioural interventions. Such networks are increasing the capacity to generate larger and more geographically representative datasets while supporting standardised trial conduct across institutions.

India is placing greater emphasis on developing domestic capabilities for First-in-Human and Phase I clinical trials. At the ICMR Annual Clinical Trial Meet in May 2026, ICMR launched a Delphi study examining regulatory pathways and opportunities for strengthening First-in-Human Phase I trials. The study involved 37 experts from pharmaceutical companies, contract research organisations, academia and regulatory agencies. ICMR identified regulatory capacity, approval processes and coordination between agencies as important areas for strengthening early-stage research. The expansion of dedicated Phase I infrastructure is expected to support earlier participation of Indian institutions in innovative drug, biologic, vaccine, cell and gene therapy development programmes.

Clinical trial sponsors in India are experiencing a regulatory environment increasingly focused on reducing administrative delays and improving coordination between regulatory and ethics-review processes. CDSCO added a parallel submission and processing mechanism for clinical trial applications and registered ethics committees in May 2026. Earlier in 2026, regulatory reforms also replaced certain permission requirements with prior-intimation mechanisms for specified low-risk research activities. CDSCO’s Global Clinical Trial Division continues to oversee multinational trials through scientific review and applications submitted through the SUGAM portal. These measures are supporting more structured trial initiation and can be particularly relevant to sponsors conducting multinational development programmes with Indian sites.

Digital health is becoming increasingly integrated into Indian clinical research, extending beyond simple electronic data capture toward remote patient monitoring, telemedicine, wearable technologies and digital outcome assessment. ICMR’s 2026 multicentre clinical trial initiative specifically identifies digital health integrations to improve clinical care as an eligible area for research. Meanwhile, Indian decentralised-trial studies have documented adoption of telemedicine, electronic patient-reported outcomes, remote monitoring and home-based visits. The increasing use of these tools is creating opportunities for continuous data collection and broader participant access. However, researchers still identify digital infrastructure investment, regulatory clarity, staff training and data-quality concerns as important requirements for wider adoption.